ADC–ICI Combo “Likely New Standard of Care” for TNBC

Results from the phase III ASCENT-04/KEYNOTE-D19 study indicate that the combination of sacituzumab govitecan, a TROP2 antibody–drug conjugate, with the PD-1 inhibitor pembrolizumab is superior to chemotherapy plus pembrolizumab for patients with PD-L1–positive advanced or metastatic triple-negative breast cancer. Disease progression risk dropped, and response rates and durability improved, , supporting the combination as a potential new standard treatment for this patient population.